Body Vision Medical Signs Exclusive Distribution Agreement with AMCO Incorporated
CoreCare and Creative Solutions in Healthcare (CSNHC) Team up to Tackle New Minimum Data Set (MDS) Challenges
Cofertility’s “State of Egg Freezing 2024” Report Reveals 30% Increase in Egg Freezing Cycles Year-Over-Year
Curiteva Surpasses 1,000 Procedures With Inspire(R) Cervical Trabecular PEEK(TM) With HAFUSE(R) Technology
6 of the Top 10 Medical Device Manufacturers Rely On AcuityMD’s Commercial Intelligence Platform to Modernize Operations, Drive Revenue
The state-of-the-art instrumentation will support and accelerate BioPharmaSpec’s clients’ efforts in successful biologics product developmentMALVERN, Pa. and ST. SAVIOUR, Jersey,...
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating...
Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO) Lixte Biotechnology Holdings, Inc. PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE)...
ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine...
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024HOUSTON, TX, June 03, 2024 (GLOBE...
Innovative Formula To Be Available in Portable Format for Enhanced Accessibility and Convenience JUPITER, FL, June 03, 2024 (GLOBE NEWSWIRE)...
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular...
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched...
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) --...
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,...
Scope of the SESHAT Project at Pioneering Hospital, Part of the Catalan Health Institute, Includes Deployment of up to 1,000...
Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) with its Cosmo Intelligent...
Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of...
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a...
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and...
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and...
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for...
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a...
